Are Patient-Reported Outcomes Predictive of Survival and Likelihood of Hospitalization?

Get Permission

In a study reported in JCO Oncology Practice, Kerrigan et al found that patient-reported outcomes (PROs), obtained by using the National Cancer Institute (NCI) Patient-Reported Outcomes Measurement Information System–Cancer (PROMIS-Ca) Bank, may be prognostic for outcomes in patients with advanced cancer.

Photo credit: Getty

Study Details

The study involved 282 patients at the Huntsman Cancer Institute with advanced melanoma, non–small cell lung cancer (NSCLC), colorectal cancer, or breast cancer who were assessed with the NCI PRO instrument in the domains of physical function, fatigue, depression, anxiety, and pain. The association of PROs, overall survival, and hospitalization-free survival were assessed in multivariate analysis that included sex and cancer type.

Key Findings

On univariate analysis, all five domains included in the instrument were strongly significantly associated with overall survival (P values of .005 to < .001) and all domains except depression were significantly associated with hospitalization-free survival (P values of .015 to < .001). The five domains were interrelated, with moderate to strong correlations (0.40–0.79).

On multivariate analysis, the physical function domain remained strongly significantly associated with overall survival and hospitalization-free survival (both P < .001).

Other significant factors on multivariate analysis were as follows:

  • NSCLC was associated with poorer overall survival vs the reference category of melanoma (P = .005)
  • Male sex was associated with significantly poorer hospitalization-free survival vs female sex (P < .001).  

The investigators concluded, “NCI PROMIS-Ca PROs may be prognostic of both cancer survival and likelihood of hospitalization. Future prospective studies are needed for all major prognostic factors to fully understand the independent prognostic value of PROs.”

Wallace Akerley, MD, of the Huntsman Cancer Institute, University of Utah, is the corresponding author for the Journal of Oncology Practice article.

Disclosure: The study was supported by the National Cancer Institute. For full disclosures of the study authors, visit

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.